explore -WSS

explore

author：explore 2025-09-14 21:42:26 - browse：68562

Dallas Mavericks owner Mark Cuban reacts during a timeout in the game against the Golden State Warriors at American Airlines Center on March 22, 2023 in Dallas, Texas. – opinion coverage from STAT — Tim Heitman/Getty Images

Mark Cuban, the Dallas Mavericks owner and “Shark Tank” star, has been making headlines recently with his direct-to-consumer venture, Cost Plus Drugs. The company sells generic prescription drugs and boasts more than 2 million members. As a family medicine specialist who has firsthand experience with American households’ dissatisfaction with the state of the nation’s prescription drug marketplace, I believe the enthusiasm for Cost Plus Drugs reveals an appetite for alternatives to the status quo in the pharmaceutical industry.

Cuban claims the reason behind the success of Cost Plus Drugs is the company’s decision to bypass pharmaceutical benefit managers — the negotiating agents insurance companies hire to negotiate big pharma’s prices down. But that might not be the case. Instead, its success appears to lie in its choice to collaborate with affordable generic drug manufacturers rather than the major pharmaceutical companies.

Last year, the Department of Health and Human Services found that between July 2021 and July 2022, major pharma companies raised the list price on more than 1,200 drugs by an average of 31 percent. That’s 23 percent more than the country’s overall inflation rate during the same period. Meanwhile, generic drug companies saved the U.S. roughly $2.6 trillion from 2012 to 2021, according to the Association for Accessible Medicines, a trade group representing generic drug manufacturers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Intellia reports positive results for its CRISPR

hotspot

WSS

Shifting the focus from loneliness to social health

When waiting feels immoral: Empathy in the emergency department

Late stage cancers on the rise after pandemic delayed screenings

CDC recommends RSV monoclonal antibody for infants

ASCO: Palliative care found as helpful given virtually as in person

Ionis drug prevents swelling attacks due to hereditary angioedema

hotspot

explore

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

How to save PrEP access — and even expand it

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Apple is now the first public company to be valued at $3 trillion

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Cancer drug shortages should be causing more outrage

CDC recommends RSV monoclonal antibody for infants

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

leisure time

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

'Null' research findings aren't empty of meaning. Let's publish them

Group behind ProMed defends move to subscription

2 officers injured in shooting in Orlando, police say

focus

hotspot

knowledge

knowledge